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I nflammatory bowel diseases (IBD) are idiopathic, chronic, relapsing intestinal disorders of complex pathogenesis, which are represented mainly by Crohn's disease (CD) and ulcerative colitis (UC). IBD is the most common and serious chronic inflammatory condition of the gastrointestinal tract and affects children and young adults in the prime of their lives and the incidence vary from 4 to 66 per 100,000 population of CD depending on the country. 1 The present view is that the initiation of IBD is due to a convergence of a genetically determined susceptibility to inflammation and environmental triggers. Several factors are known to initiate relapses, including infection, ingestion of nonsteroidal anti-inflammatory drugs, stress, and nicotine. It has been shown that nicotine can exert 2 distinct effects in IBD: ameliorating or worsening the colitis in UC and CD patients. 2 Recently, a clinical study demonstrated that relapse rates for CD ranged from 10% to 60% and 11% to 90% for UC. 3 Depression results from a combination of genetic, environmental, and psychologic factors. Depression is associated with variety of medical conditions, which include irritable bowel syndromes, IBD, and also ischemic heart disease particularly in men. 4 There are 2 broad hypotheses to explain this relationship, and they relate to inflammation or to autonomic imbalance. Major depression is strongly associated with increased levels of C-reactive protein (CRP) among men. 5 Depression was also associated with increases in inflammation and coagulation factors in individuals who were free of cardiovascular disease, offering a stronger link between depression per se and susceptibility to inflammation. 6 Indeed, some depressed patients exhibited increased tumor necrosis factor-␣ level, which normalized upon treatment with antidepressants. 7 It remains unclear as to whether this relationship reflects either a causal role for depression in susceptibility to inflammatory stimuli or common inflammation-based etiopathology. 8, 9 The second broad hypothesis is that depression results in autonomic imbalance, with impaired parasympathomimetic functions 10 and a dominant sympathetic drive contributing to cardiac pathophysiology. 11 The notion that depression is associated with parasympathetic dysfunction has led to the exploitation of vagal electrical stimulation as a novel treatment for refractory depression. 12 Depression may coexist with CD more often than expected by chance. 13 In some studies, depression was unrelated to disease activity 14 and, in some cases, actually predated the onset of CD. 15 However, in other studies, depression correlated well with disease activity, suggesting that it is secondary to the disability imposed by CD. 16 We postulate that depression influences the natural history of IBD. Recently, we have demonstrated that the vagus nerve provides tonic inhibition of acute inflammation in a murine model of colitis. 17 We have also provided proof of concept that depressive-like behavior is associated with an exaggerated response to acute inflammatory stimuli in the gut via a vagal nerve-dependent pathway. 18 Given the psychiatric comorbitidy seen in IBD, we have investigated whether the development of depression after the establishment of chronic inflammation reactivates an acute relapse of IBD and have examined underlying pharmacologic mechanisms.
To achieve this, we used a lymphocyte-independent model of chronic colitis induced by oral administration of dextran sulfate sodium (DSS) 19 and a lymphocytedependent model induced by intracolonic administration of 2,4 dinitrobenzenesulfonic acid (DNBS). 20 We then induced depression using 2 established models: intracerebroventricular (ICV) reserpine treatment 18 and bilateral olfactory bulbelctomy. 21 Thus, depression was induced on a background of quiescent inflammation and more closely resembling the natural history of chronic IBD. We also examined whether the reactivation involves changes in barrier function, as previously described with stressinduced reactivation of colitis. 22 The recent demonstrations of a tonic counter-inflammatory influence of the vagus nerve on experimental colitis mediated via the ␣7 subunit of the nicotinic acetylcholine receptor (␣7nAchR) 23 provides a potential link between the cholinergic pathways via the nicotinic receptors, behavior, and gut inflammation. 17 We also examined whether the vagus nerve, ␣7nAchR, and cytokine production by macrophages are involved. Of potential clinical importance, we investigated whether depression-induced reactivation could be prevented by antidepressants or by agonists of the nicotinic acetylcholine receptor.
Materials and Methods

Animals
Male C57BL/6 (7-9 weeks old) and ␣7nAchR-deficient mice (B6.12957-Chrna7 tm1bay ) breeding pairs were purchased from Taconic Farms Suppliers (Albany, NY) and Jackson Laboratories (Bar Harbor, ME) and maintained single housed in the animal care facility at McMaster University under specific pathogen-free conditions after surgery. All experiments were approved by the McMaster University Animal Ethics Committee and conducted under the Canadian guidelines for animal research.
Induction of Chronic DSS and DNBS Colitis
DSS (40 kilodaltons; MP Biomedicals, Soho, Ohio) was added to the drinking water in a final concentration of 5% (wt/vol) for 5 days then mice were given standard water for 11 days. Cycle was repeated twice with 3% DSS. In a second set, mice were anesthetized with Isoflurane (Abbott, Toronto, Ontario, Canada). A 10-cmlong PE-90 tubing (ClayAdam, Parsippany, NJ), attached to a tuberculin syringe, was inserted (intrarectally) 3.5 cm into the colon. Colitis was induced by intrarectal administration of 100 L of 4 mg of DNBS solution (ICN Biomedical Inc, Aurora, OH) in 30% ethanol, and the mice were left for 3 days. Control mice (without colitis) received saline administration. Mice with colitis were supplied with 6% sucrose in drinking water to prevent dehydration.
Surgical Procedures and Reactivation of Colitis
Forty-eight, 52, and 57 days after the induction of colitis by DSS or DNBS, microosmotic pumps (MOP) (Alzet, Cupertino, CA) were filled with reserpine solution (1 g/day for 14 days) or vehicle, choline-chloride (CC) (2 g/day, 10 days), or methyllycaconitine (MLA) (5 g/day, 5 days) (Sigma-Aldrich, Mississaugua, Ontario, Canada), respectively, 24 all dissolved in water expect for reserpine diluted in (acetic acid 0.2%, pH balanced to 5). In another group, the MOP was placed directly in the peritoneum and was loaded with the same dose of reserpine or the vehicle. Bilateral ablation of the olfactory bulbs was performed using methods similar to those described previously. 25 Next, colitis was reactivated on days 57 and 59 by DSS 2% or DNBS 2 mg. At the end of the experimental protocols, the brains of the mice were removed, and the completeness of olfactory bulb removal was verified by histology (data not shown). Vagotomy associated with a pyloroplasty and its assessment on acute colitis (DSS 5%) in ␣7nAchR-deficient mice were performed using methods similar to those described previously. 18 Parts of the experimental protocols are described Figure 1 .
Drugs
As previously described, 18 desmethylimipramine (DMI) (Sigma-Aldrich) was administrated intraperitoneally (IP) at the dose of 15 mg/kg for 12 days starting 2 days postsurgery (day 50), nicotine or CC (20 g/mL) were added to the drinking water on day 4 postsurgery (day 52), and hexamethonium or MLA (5 mg/kg) were administered by subcutaneous injection twice a day for 5 days post-DSS.
Tail Test
The immobility latency and the total duration of immobility induced by tail suspension was measured according to the method described by Steru et al. 26 This test is widely used in screening antidepressant drugs.
CRP and Cytokines Assays
Blood was collected, 5 or 3 days postreactivation associated with DSS or DNBS, respectively, by intracardiac puncture under Isoflurane anesthesia. Colonic sample were prepared as previously described, 18 and CRP level, interleukin (IL)-1␤, and IL-6 were determined using enzyme-linked immunosorbent assay commercial kit (R&D Systems, Minneapolis, MN).
Characterization of Inflammation
Disease activity index (DAI) and macroscopic scores and colonic damage were performed using a previously described scoring system for DSS colitis 17, 27 and for DNBS. 17, 28 Formalin-fixed colon segments coming from the splenic flexure were stained with H&E. 17 Myeloperoxidase (MPO) activity was determined following an established protocol. 29 
Isolation of Peritoneal Macrophages
Resident peritoneal cells were collected 5 or 3 days postreactivation associated with DSS or DNBS, respectively, as described 30 with a slight modification. Cells were collected and resuspended in Dulbecco's modified Eagle medium (DMEM) at 1 ϫ 10 6 cells/mL. The overall cell viability was greater than 97%, and more than 94% of the cells were macrophages using DiffQuick (Jorgensen Laboratory, Loveland, CO) staining. Macrophage cultures were then exposed to CC (10 Ϫ6 mol/L) or to interferon (INF)-␥ (150 IU/mL Ϫ1 ) (Sigma-Aldrich) where indicated. Ten minutes after the addition of the agents, lipopolysaccharide (LPS) (Sigma-Aldrich) was added to the cultures at a final concentration of 100 ng/mL Ϫ1 . Supernatants were collected 3 hours after the addition of LPS.
Macrophage Staining
Five or 3 days postreactivation associated with DSS or DNBS treatment, respectively, F4/80 staining was performed using methods similar to those described previously. 31 Briefly, sections were incubated with monoclonal rat anti-mouse antibody F4/80 (1:100, 18 hours at 4°C; Serotec, Raleigh, NC) then incubated with biotinylated goat anti-rat IgG antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hour followed by horseradish peroxidase-conjugated streptoavidin (1:300; DakoCytomation, Carpinteria, CA) for 30 minutes. 
Colonic Barrier Function
Five days postreactivation with DSS, segments of the distal colon were mounted in ussing chambers (WP Instruments, Longmont, CO), with a 0.6-cm 2 serosal tissue area exposed to oxygenated Krebs buffer maintained at 37°C, and colonic barrier function was assessed using methods similar to those described previously. 32 Electrical current was measured in the voltage-clamp mode and expressed as short-circuit current (Isc; A/cm 2 ). Tissue conductance (G; mS/cm 2 ), which measures passive ion transport and represents paracellular barrier function, was assessed.
Statistical Analysis
Results are presented as means Ϯ SEM. Statistical analysis was performed using 1-or 2-way ANOVA followed by the Tukey-Kramer multiple comparisons post hoc analysis, and a P value of Ͻ.05 was considered significant with n Ͼ 8 (KyPlot; KyensLab Inc, Soto Kando, Japan) (See Supplementary Materials and Methods).
Results
The Induction and Resolution of Chronic Colitis
In C57Bl/6 mice, acute administration of DSS 2% or 2 mg of DNBS have no effect on MPO activity or on CRP level and proinflammatory cytokines 5 and 3 days postinduction, respectively (data not shown). Chronic colitis was induced by 3 cycles of DSS 5%-3%-3%, 30 days after the beginning of the last cycle. The residual macroscopic score, MPO, CRP, IL-6, and IL-1␤ levels were 0.6 Ϯ 0.2, 0.3 Ϯ 0.1 U/mg, 17.4 Ϯ 0.8 ng/mL, 0.9 Ϯ 0.5 pg/mg, and 31.1 Ϯ 8.4 pg/mg, respectively, compared with 0.9 Ϯ 0.4, 0.5 Ϯ 0.4 U/mg, 15.3 Ϯ 2.8 ng/mL, 1.4 Ϯ 0.8 pg/mg, and 37.2 Ϯ 6.3 pg/mg, respectively, to the naïve group (P Ͼ .05). In a second set of mice, we used a single intrarectal administration of DNBS (4 mg) as another inflammatory stimulus, and this resulted in a severe colitis, characterized by extensive tissue damage and a large acute inflammatory cell infiltrate, with a macroscopic score of 3.7 Ϯ 0.4 and a significant increase in MPO activity, from 0.7 Ϯ 0.4 to 1.7 Ϯ 0.3 U/mg after 3 days of treatment. These changes lasted several weeks, but the tissue appeared normal at day 62 (macroscopic score, 1.8 Ϯ 0.5; MPO activity, 0.8 Ϯ 0.3 U/mg; and IL-6 level, 3.4 Ϯ 0.7 pg/mg compared with 2.1 Ϯ 0.4, 1.3 Ϯ 0.4 U/mg, 5.4 Ϯ 1.8 pg/mg, respectively, to the naïve group).
The Effect of Depression on Quiescent Colitis in Mice
When mice were tested using the tail suspension test 8 days postsurgery, chronic ICV infusion of reserpine (1 g/day, 14 days) significantly increased the duration of immobility and reduced the latency to immobility. Immobility duration and latency duration were 172.3 Ϯ 11.8 and 27.8 Ϯ 3.3 seconds in reserpinized mice (RM) group and 124.2 Ϯ 5.1 and 62.5 Ϯ 6.1 seconds in sham group, respectively (P Ͻ .05). RM showed a more severe reactivation of the colitis compared with vehicle mice (non-RM) treated or not with 2% DSS. Macroscopic scores, MPO, and CRP levels increased from 3.2 Ϯ 0.3 to 6.2 Ϯ 0.4, 2.7 Ϯ 0.2 to 4.1 Ϯ 0.3 U/mg, 29.1 Ϯ 1.7 to 42.7 Ϯ 2.1 ng/mL, respectively, following reactivation with 2% DSS and from 0.6 Ϯ 0.2 to 2.9 Ϯ 0.2, 0.83 Ϯ 0.2 to 3.4 Ϯ 0.5 U/mg, 17.4 Ϯ 0.8 to 23.4 Ϯ 0.7 ng/mL, respectively, in the absence of reactivation. Histologic score, IL-6, and IL-1␤ levels in colonic tissues were 71%, 46%, 66%, respectively, higher in RM-treated compared with non-RM treated with 2% DSS (Figure 2A and 2E) and 107%, 122%, and 243%, respectively, higher in the absence of reactivation (Figure 2A-E) .
We next examined whether the effect of reserpine could be modulated by the treatment with antidepressant. DMI had no effect on any parameter of inflammation in mice with colitis that had not received reserpine (Figure 2) . DMI therapy significantly improved the pa- rameters of depressive-like behavior; immobility duration and latency duration were 100.2 Ϯ 7.1 and 52.3 Ϯ 3.1 seconds, respectively, in RM group and also reduced the vulnerability when treated or not with 2% DSS. Macroscopic scores, MPO, and CRP levels were significantly decreased to 2.7 Ϯ 0.3, 2.6 Ϯ 0.2 U/mg, 32.2 Ϯ 2.1 ng/mL, respectively, in RM-DMI-treated compared with RM following reactivation with 2% DSS and to 0.8 Ϯ 0.3, 1.1 Ϯ 0.2 U/mg, 20.1 Ϯ 0.4 ng/mL, respectively, without reactivation. Histologic score, IL-6, and IL-1␤ tissue levels were 34%, 98%, 46% lower in RM-DMI-treated compared with RM following reactivation with 2% DSS and 71%, 91%, and 80% lower without reactivation, respectively (Figure 2 ).
To exclude a direct effect of reserpine infused ICV on colitis, the same dose of reserpine was given into the peritoneum via a MOP at 1 g/day for 14 days; reserpine did not modify the colitis in mice in the absence of preexisting depression (Supplementary Figure 1) . Reserpine and DMI treatments showed the same results when chronic DNBS colitis was reactivated or not ( Table 1) .
Effect of Depression on Colonic Barrier Function
We next evaluated whether colonic barrier function, as assesed by ion transport and conductance, was affected when the colitis was reactivated without any new DSS challenge. No statistically significant changes were found in barrier function in mice that had recovered from chronic DSS colitis previously and subject to depression or subject to depression and treated with DMI. The short-circuit current (Isc) values were 65.1 Ϯ 6.6, 53.9 Ϯ 11.1, and 83.1 Ϯ 11.4 A/cm 2 , respectively. The conductance, reflecting the paracellular transport, was not significantly changed in RM-DMI treated mice; RMtreated mice compared with nontreated mice. Values were, respectively, 24.5 Ϯ 2.4, 25.9 Ϯ 2.3, and 22.4 Ϯ 3.2 ms/cm 2 .
Role of the ␣7nAchR
Next, we examined whether treatment with selective choline-chloride and methyllycaconitine, respectively, ␣7nAchR agonist and antagonist, influences the depression-induced reactivation of colitis. Treatment with CC significantly decreased all inflammatory markers in RM. Conversely, MLA did not increase further the inflammatory markers in those mice when reactivated with DSS 2%, except for the macroscopic scores (Supplementary Figure 2 ). In the absence of reactivation, CC also decreased the macroscopic scores, MPO, IL-6, and IL-1␤ by 78%, 44%, 34%, and 54%, respectively, in RM (Figure 3) . No significant changes were seen when treated with MLA. In contrast, in RM treated with DMI, MLA abolished the beneficial effect of the antidepressant on reactivation by depression. Macroscopic scores and MPO were increased by 3.5-and 4.9-fold, respectively, and IL-6 and IL-1␤ by 5.9-and 12-fold, respectively. 
BASIC-ALIMENTARY TRACT
To determine whether MLA and CC act centrally when injected peripherally, we then administered these agents ICV. Neither MLA or CC modified the reactivation of colitis in mice without depression (Supplementary Figure  3) . These results indicate that the ␣7nAchR is critical for the reactivation of colitis by depression.
To confirm the role of the ␣7nAchR on DSS colitis, we used ␣7-deficient mice. However, these knockout mice did not survive a second cycle of DSS treatment (Supplementary Figure 4 ). Experiments were performed using a single trial of 5 days of DSS 5%, which induced acute colitis. The absence of ␣7nAchR accelerated the onset of loose stools, weight loss, and rectal bleeding. On day 3 postcolitis induction, 55% and 95% of ␣7-deficient DSStreated mice had rectal bleeding and weight loss, respectively, compared with 30% and 70%, respectively, of wildtype DSS-treated mice (P Ͻ .05) (data not shown). On day 5 postcolitis induction, macroscopic scores, MPO, and CRP levels were 111%, 73%, and 35%, respectively, higher in ␣7-deficient DSS-treated mice compared with wild-type ( Figure 4A and 4B ). IL-6 and IL-1␤ tissue levels were 31% and 96%, respectively, higher in ␣7-deficient DSS-treated mice ( Figure 4C ). Histologic scores increased from 1.8 Ϯ 0.4 to 3.7 Ϯ 0.6 in ␣-7-deficient DSS-treated mice compared with wild-type DSS treated, respectively. Pretreatment with nicotine or CC significantly decreased these markers in DSS-treated wild-type mice, but no differences were seen in ␣7-deficient mice treated with nicotine. Hexamethonium or MLA treatment significantly increased these markers in the wild-type DSStreated mice, but no differences were seen in ␣-7-deficient mice treated with hexamethonium. Vagotomy had no effect on the colitis in ␣7-deficient mice (Figure 4) . These data confirm the role of this receptor in the expression of colitis.
Effect of Depression on Macrophages
We next assessed the functional role of the macrophage in the reactivation of colitis induce by depressive-like behavior. Reactivation of colitis without any new DSS challenge was associated with a transmural infiltrate of F4/80 ϩ macrophages in non-RM and RM treated or not with antidepressant. F4/80 ϩ cells were evident in mucosa, submucosa, and muscle layers in mice with previous chronic colitis ( Figure 5A ). To determine whether the macrophage sensitivity was modified by depression, we examined the cytokine release from intraperitoneal macrophages ( Figure 5B ). We stimulated cultured mouse macrophages with LPS (100 ng/mL Ϫ1 ) and treated them with CC (10 Ϫ6 mol/L) or INF-␥ (150 IU/ mL Ϫ1 ). Cells from depressed mice revealed an increased release of IL-6 and IL-1␤ following LPS stimulation compared with nondepressed mice. However, this was not evident in macrophages issued from TCA-treated, depressed mice. To determine the capacity of these cells from nondepressed mice to produce proinflammatory cytokines, we costimulated cells with INF-␥ and achieved a similar level of secretion of IL-6 and IL-1␤ as was seen in macrophages from depressed mice. Because CC attenuates the effect on depressed mice in vivo, we next examined whether it could decrease the release of cytokine on macrophage isolated from depressed mice. As reported, CC decreased significantly IL-6 and IL-1␤ ( Figure 5 ).
Effect of Bilateral Olfactory Bulbectomy on Quiescent Colitis in Mice and Cultured Macrophages
To determine the specificity of our findings with reserpine, we used another model of depression that is well established in the literature 25 : the model of bilateral olfactory bulbectomy (Obx). On day 7 postsurgery, 50% Obx mice had loose stools compared with 12.5% of shamoperated, DSS-treated mice ( Figure 6A ). Obx mice exhibited a more severe reactivation of the colitis compared with sham mice treated or not with 2% DSS. The effect of Obx was significantly decreased when mice were treated with DMI ( Figure 6B ). The assessment of the functional role of the macrophage in the reactivation of colitis induced by Obx revealed a profile similar to that found in the reserpine model ( Figure 6B ).
Discussion
Depression is common in IBD and most likely reflects the morbidity associated with these conditions. The results of this study provide proof of concept that depression per se can reactivate intestinal inflammation in mice in which chronic inflammation had been induced and allowed to become clinically quiescent. This model is reminiscent of the clinical scenario in which depression may occur during the natural history of IBD. Our results show that the induction of depression reactivates gut inflammation in 2 experimental models of colitis by attenuating the ␣7nAchR-mediated vagal suppression of proinflammatory cytokine release from macrophages. Furthermore, we showed that treatment with TCA attenuates this depression-induced reactivation of gut inflammation. These results have clinical and scientific implications in the management and understanding of chronic intestinal inflammation. A major observation is the finding that TCA inhibited the reactivation of colitis by depression. Critical to this interpretation is the finding that TCA did not influence inflammation in the absence of depression. We are aware of the possibility that the TCA may have direct antiinflammatory effects, 33 but these were not evident in our experiments. DMI had no effect on any parameter of inflammation in DSStreated mice without depression.
Nicotinic acetylcholine receptors (nAchR) are present along the gastrointestinal tract of animal and human, 34 and there are reports that nicotine interacts with the ␣7nAchR on macrophages. 35 We hypothesized a possible association among ␣7nAchR, depression, pathogenesis, and course of intestinal inflammation. Our results are consistent with the notion showing that the tricyclic antidepressant DMI attenuates the inflammatory response in RM by enhancing parasympathetic function. 18 First, the deleterious effect of depression on reactivation of colitis is absent in CC-treated mice. Moreover, MLA therapy did not up-regulate inflammation in depressed mice. Second, the beneficial effect of DMI was absent in MLA-treated mice in the absence of reactivation of colitis, and treatment with CC did not further decrease the inflammatory markers. Whereas it is known that nicotine has antidepressive effects 36 that could affect vagal activity and influence the effects of MLA and CC peripherally, we found no evidence of a central effect of these compounds on colitis.
We confirmed a major role of the ␣7nAchR in depression-induced reactivation because ␣7-deficient mice showed an increased severity colitis induced by DSS and neither the receptor agonist nor the antagonist modulated the degree of inflammation in ␣7-deficient mice. In addition, vagotomy did not influence the severity of colitis in ␣7-deficient mice. The importance of ␣7 receptor in our model is similar to that found in sepsis 35 and pancreatis. 37 Macrophages are an important component of the inflammatory response in murine models 38 and in human IBD 39 and are responsible for the production of proinflammatory cytokines. 40 Several groups have identified the ␣7nAchR on human and murine macrophages. 34, 41, 42 In vitro examination of intraperitoneal macrophages from depressed mice revealed an increased release of proinflammatory cytokines following LPS stimulation and that was not evident in CC-treated macrophages or cells issued from TCA-treated, depressed mice. This is further supported by demonstrations in vitro that ␣7nAchR are involved in the selective down-regulation of LPS-induced release of tumor necrosis factor-␣, IL-6, and IL-1␤ in cultured macrophages. 23 We conclude that the effect of depression is accompanied by macrophage impairment associated with an increase of sensitivity of these cells to LPS.
It is likely that other factors contributed to the deleterious effect of depression on colitis in our study. Parasympathetic impairment results in a dominant sympathetic drive, and it is known that this can enhance or decrease colonic inflammation. 43, 44 In addition, a decrease of the vagal activity alters lymphocyte trafficking 45 and mast cell numbers in the gut 46 and influences gut physiology, 47 and these factors could contribute to the changes in severity of the reactivation of colitis seen in our study. In addition to macrophages, nicotine alters various neutrophil functions such as chemotaxis 48 and superoxide anion production. 49 However, although neutrophils express nicotinic receptors, 50 it is yet unclear whether these effects are mediated by the ␣7nAchR. In contrast to previously published data on stress reactivation 22 of colitis, the reactivation seen here is not due to changes in intestinal barrier function.
In conclusion, the present study provides proof of concept that depression reactivates quiescent inflammation in the bowel and elucidates the underlying pharmacologic mechanism. These findings have important clinical implications because they clarify uncertainty regarding the link between depression and IBD. 51 Our results emphasize a causal linkage between depression and relapse of IBD and encourage close monitoring of depressive behavior in IBD patients. The results demonstrate a role for antidepressants in stabilizing the natural history of the disease and provide a basis for considering trials of highly selective nAchR agonists 41, 52 to prevent relapses in patients with IBD and depression.
per milligram of wet tissue, 1 unit being the quantity of enzyme able to convert 1 mM of hydrogen peroxide to water in 1 minute at room temperature.
Macrophages staining. Serial sections were deparaffinized in CitriSolv (Fisher Scientific, Illkirch, France) and rehydrated through a graded series of ethyl alcohol and PBS. Endogenous peroxide was blocked by an incubation in peroxidase blocking reagent (DakoCytomation, Carpinteria, CA) for 15 min. After being washed, sections were predigested with proteinase K solution (DakoCytomation) for 15 min at room temperature or were subjected to antigen retrieval in citrate buffer (pH 6.0) after being heated in a microwave. After being washed and blocked of nonspecific binding with 1.0% BSA in PBS, sections were incubated with monoclonal rat anti-mouse antibody F4/80 (Serotec, Raleigh, NC, 1:100, 18 h at 4°C). After being washed, sections stained for F4/80 immunostaining were incubated with biotinylated goat anti-rat IgG antibody (Santa Cruz Biotechnology, Santa Cruz, CA, 1:200) for 1 h followed by horseradish peroxidase-conjugated streptoavidin (DakoCytomation, 1:300) for 30 min. Sections were developed with 3,3=-diaminobenzidine solution as a chromogen. They were counterstained with Meyer's hematoxylin (DakoCytomation), dehydrated, cleared, and mounted. Negative controls were prepared by omission of the primary antibodies.
